SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Lovenox

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 1993. Ex-US commercial rights being transferred to Cheplapharm expected Q1 2027.
Why 3/10
No hard, dated binary catalyst exists for Lovenox in the next ~12 months. It is an already-approved, off-patent drug with no pending FDA decision, no pivotal readout, and no scheduled regulatory action. The Cheplapharm deal closing (Q1 2027) is a commercial transfer, not a binary event. Per the rubric, an approved drug with no pending regulatory decision scores 3-5, and Lovenox is a small, declining part of a large diversified pipeline, warranting a 3.
Actionable Insight NEUTRAL

Lovenox has no upcoming binary catalysts. The key event to watch is the closing of the Cheplapharm partnership (expected Q1 2027), which transfers ex-US Lovenox rights in exchange for a 26.4% stake in Cheplapharm. This is a portfolio cleanup, not a value-creating catalyst for Sanofi shares. For Sanofi investors, the focus should remain on growth drivers like Dupixent and the pipeline, not this declining legacy asset.

Price Chart

Loading chart...

Executive Summary

Lovenox (enoxaparin sodium) is Sanofi's brand-name injectable blood thinner, first FDA-approved in 1993 for preventing and treating blood clots. The drug is now off-patent with extensive generic competition, and its sales are steadily declining (EUR 174M in Q3 2026, down 12.8% YoY). In September 2026, Sanofi announced a strategic partnership to transfer ex-US rights to Lovenox and 19 other mature medicines to Cheplapharm in exchange for a 26.4% equity stake, with commercial transfer expected in Q1 2027. Lovenox is a small and shrinking part of Sanofi's diversified portfolio and has no upcoming binary catalysts that would materially move the stock.

How It Works

Lovenox is a low molecular weight heparin (LMWH), an injectable blood thinner. It works by activating antithrombin III, a natural protein in the body that stops blood clots from forming. It is used to prevent deep vein thrombosis (DVT) after surgery, to treat existing blood clots, and to manage certain types of heart attacks.

Trial Status

Lovenox is a fully approved, commercially marketed drug. No active pivotal trials are being conducted by Sanofi for this molecule. It is used as an active comparator in third-party Phase 2/3 trials testing new anticoagulants.

The Two-Sided Case

▲ Bull Case3
Lovenox remains a clinically important hospital anticoagulant with entrenched usage in DVT prophylaxis and ACS, generating EUR 174M in Q3 2026 alone.
The Cheplapharm partnership (26.4% equity stake) lets Sanofi retain upside from the mature medicines portfolio while offloading manufacturing and commercial costs.
Sanofi's Q3 2026 earnings beat estimates and the company raised full-year guidance, showing the overall business is strong even as legacy assets like Lovenox decline.
▼ Bear Case3
Lovenox is a mature, off-patent drug facing extensive generic and biosimilar competition in both the US and Europe, driving persistent revenue declines (Q3 2026 sales down 12.8% YoY to EUR 174M).
Sanofi is actively divesting the asset: the September 2026 Cheplapharm deal transfers ex-US Lovenox rights, signaling the drug is no longer core to Sanofi's innovation-focused strategy.
Oral anticoagulants (e.g., apixaban/Eliquis, rivaroxaban/Xarelto) continue to erode the injectable LMWH market, structurally pressuring Lovenox's long-term relevance.

Upcoming Catalysts

  • Closing of Cheplapharm partnership transferring ex-US Lovenox rights (expected Q1 2027)
  • Continued quarterly sales declines as generic/biosimilar competition intensifies

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 7

Hover a chip for the title
1 sanofi.com2 sanofi.com3 accessdata.fda.gov4 fda.gov5 pharmacompass.com6 novapharmanews.com7 fiercepharma.com